Bleselumab

Profil Farmakokinetik

Waktu Paruh (Half-Life) -

Volume Distribusi -

Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

669 Data

Denosumab	The risk or severity of adverse effects can be increased when Denosumab is combined with Bleselumab.
Etanercept	The risk or severity of adverse effects can be increased when Etanercept is combined with Bleselumab.
Peginterferon alfa-2a	The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Bleselumab.
Interferon alfa-n1	The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Bleselumab.
Interferon alfa-n3	The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Bleselumab.
Peginterferon alfa-2b	The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Bleselumab.
Anakinra	The risk or severity of adverse effects can be increased when Anakinra is combined with Bleselumab.
Interferon gamma-1b	The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Bleselumab.
Interferon alfa-2a	The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Bleselumab.
Aldesleukin	The risk or severity of adverse effects can be increased when Aldesleukin is combined with Bleselumab.
Adalimumab	The risk or severity of adverse effects can be increased when Adalimumab is combined with Bleselumab.
Gemtuzumab ozogamicin	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Bleselumab.
Pegaspargase	The risk or severity of adverse effects can be increased when Pegaspargase is combined with Bleselumab.
Infliximab	The risk or severity of adverse effects can be increased when Infliximab is combined with Bleselumab.
Interferon beta-1b	The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Bleselumab.
Interferon alfacon-1	The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Bleselumab.
Rituximab	The risk or severity of adverse effects can be increased when Rituximab is combined with Bleselumab.
Basiliximab	The risk or severity of adverse effects can be increased when Basiliximab is combined with Bleselumab.
Muromonab	The risk or severity of adverse effects can be increased when Muromonab is combined with Bleselumab.
Ibritumomab tiuxetan	The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Bleselumab.
Tositumomab	The risk or severity of adverse effects can be increased when Tositumomab is combined with Bleselumab.
Alemtuzumab	The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Bleselumab.
Alefacept	The risk or severity of adverse effects can be increased when Alefacept is combined with Bleselumab.
Efalizumab	The risk or severity of adverse effects can be increased when Efalizumab is combined with Bleselumab.
Antithymocyte immunoglobulin (rabbit)	The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Bleselumab.
Interferon alfa-2b	The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Bleselumab.
Daclizumab	The risk or severity of adverse effects can be increased when Daclizumab is combined with Bleselumab.
Phenylalanine	The risk or severity of adverse effects can be increased when Phenylalanine is combined with Bleselumab.
Flunisolide	The risk or severity of adverse effects can be increased when Flunisolide is combined with Bleselumab.
Bortezomib	The risk or severity of adverse effects can be increased when Bortezomib is combined with Bleselumab.
Cladribine	Bleselumab may increase the immunosuppressive activities of Cladribine.
Carmustine	The risk or severity of adverse effects can be increased when Carmustine is combined with Bleselumab.
Amsacrine	The risk or severity of adverse effects can be increased when Amsacrine is combined with Bleselumab.
Bleomycin	The risk or severity of adverse effects can be increased when Bleomycin is combined with Bleselumab.
Chlorambucil	The risk or severity of adverse effects can be increased when Chlorambucil is combined with Bleselumab.
Raltitrexed	The risk or severity of adverse effects can be increased when Raltitrexed is combined with Bleselumab.
Mitomycin	The risk or severity of adverse effects can be increased when Mitomycin is combined with Bleselumab.
Bexarotene	The risk or severity of adverse effects can be increased when Bexarotene is combined with Bleselumab.
Vindesine	The risk or severity of adverse effects can be increased when Vindesine is combined with Bleselumab.
Floxuridine	The risk or severity of adverse effects can be increased when Floxuridine is combined with Bleselumab.
Indomethacin	The risk or severity of adverse effects can be increased when Indomethacin is combined with Bleselumab.
Tioguanine	The risk or severity of adverse effects can be increased when Tioguanine is combined with Bleselumab.
Vinorelbine	The risk or severity of adverse effects can be increased when Vinorelbine is combined with Bleselumab.
Dexrazoxane	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Bleselumab.
Beclomethasone dipropionate	The risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Bleselumab.
Sorafenib	The risk or severity of adverse effects can be increased when Sorafenib is combined with Bleselumab.
Streptozocin	The risk or severity of adverse effects can be increased when Streptozocin is combined with Bleselumab.
Trifluridine	The risk or severity of adverse effects can be increased when Trifluridine is combined with Bleselumab.
Gemcitabine	The risk or severity of adverse effects can be increased when Gemcitabine is combined with Bleselumab.
Betamethasone	The risk or severity of adverse effects can be increased when Betamethasone is combined with Bleselumab.
Teniposide	The risk or severity of adverse effects can be increased when Teniposide is combined with Bleselumab.
Epirubicin	The risk or severity of adverse effects can be increased when Epirubicin is combined with Bleselumab.
Chloramphenicol	The risk or severity of adverse effects can be increased when Chloramphenicol is combined with Bleselumab.
Lenalidomide	The risk or severity of adverse effects can be increased when Lenalidomide is combined with Bleselumab.
Altretamine	The risk or severity of adverse effects can be increased when Altretamine is combined with Bleselumab.
Zidovudine	The risk or severity of adverse effects can be increased when Zidovudine is combined with Bleselumab.
Cisplatin	The risk or severity of adverse effects can be increased when Cisplatin is combined with Bleselumab.
Oxaliplatin	The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Bleselumab.
Cyclophosphamide	The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Bleselumab.
Vincristine	The risk or severity of adverse effects can be increased when Vincristine is combined with Bleselumab.
Fluorouracil	The risk or severity of adverse effects can be increased when Fluorouracil is combined with Bleselumab.
Propylthiouracil	The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Bleselumab.
Pentostatin	The risk or severity of adverse effects can be increased when Pentostatin is combined with Bleselumab.
Methotrexate	The risk or severity of adverse effects can be increased when Methotrexate is combined with Bleselumab.
Carbamazepine	The risk or severity of adverse effects can be increased when Carbamazepine is combined with Bleselumab.
Vinblastine	The risk or severity of adverse effects can be increased when Vinblastine is combined with Bleselumab.
Fluticasone propionate	The risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Bleselumab.
Fluocinolone acetonide	The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Bleselumab.
Linezolid	The risk or severity of adverse effects can be increased when Linezolid is combined with Bleselumab.
Imatinib	The risk or severity of adverse effects can be increased when Imatinib is combined with Bleselumab.
Triamcinolone	The risk or severity of adverse effects can be increased when Triamcinolone is combined with Bleselumab.
Clofarabine	The risk or severity of adverse effects can be increased when Clofarabine is combined with Bleselumab.
Prednisone	The risk or severity of adverse effects can be increased when Prednisone is combined with Bleselumab.
Pemetrexed	The risk or severity of adverse effects can be increased when Pemetrexed is combined with Bleselumab.
Fludrocortisone	The risk or severity of adverse effects can be increased when Fludrocortisone is combined with Bleselumab.
Mycophenolate mofetil	The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Bleselumab.
Daunorubicin	The risk or severity of adverse effects can be increased when Daunorubicin is combined with Bleselumab.
Irinotecan	The risk or severity of adverse effects can be increased when Irinotecan is combined with Bleselumab.
Methimazole	The risk or severity of adverse effects can be increased when Methimazole is combined with Bleselumab.
Etoposide	The risk or severity of adverse effects can be increased when Etoposide is combined with Bleselumab.
Sulfasalazine	The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Bleselumab.
Dacarbazine	The risk or severity of adverse effects can be increased when Dacarbazine is combined with Bleselumab.
Temozolomide	The risk or severity of adverse effects can be increased when Temozolomide is combined with Bleselumab.
Penicillamine	The risk or severity of adverse effects can be increased when Penicillamine is combined with Bleselumab.
Prednisolone	The risk or severity of adverse effects can be increased when Prednisolone is combined with Bleselumab.
Sirolimus	The risk or severity of adverse effects can be increased when Sirolimus is combined with Bleselumab.
Mechlorethamine	The risk or severity of adverse effects can be increased when Mechlorethamine is combined with Bleselumab.
Azacitidine	The risk or severity of adverse effects can be increased when Azacitidine is combined with Bleselumab.
Carboplatin	The risk or severity of adverse effects can be increased when Carboplatin is combined with Bleselumab.
Methylprednisolone	The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Bleselumab.
Dactinomycin	The risk or severity of adverse effects can be increased when Dactinomycin is combined with Bleselumab.
Cytarabine	The risk or severity of adverse effects can be increased when Cytarabine is combined with Bleselumab.
Azathioprine	The risk or severity of adverse effects can be increased when Azathioprine is combined with Bleselumab.
Doxorubicin	The risk or severity of adverse effects can be increased when Doxorubicin is combined with Bleselumab.
Hydroxyurea	The risk or severity of adverse effects can be increased when Hydroxyurea is combined with Bleselumab.
Busulfan	The risk or severity of adverse effects can be increased when Busulfan is combined with Bleselumab.
Mycophenolic acid	The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Bleselumab.
Topotecan	The risk or severity of adverse effects can be increased when Topotecan is combined with Bleselumab.
Mercaptopurine	The risk or severity of adverse effects can be increased when Mercaptopurine is combined with Bleselumab.
Thalidomide	The risk or severity of adverse effects can be increased when Thalidomide is combined with Bleselumab.

Referensi & Sumber

Belum ada data referensi/link/attachment untuk obat ini pada database. Jalankan import DrugBank untuk mengisi field referensi.

Contoh Produk & Brand

Produk: 0 • International brands: 0

Belum ada data produk/brand untuk obat ini pada database. Jalankan import DrugBank untuk mengisi field produk/brand.

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.

Deskripsi

Struktur Molekul 2D

Deskripsi metode visualisasi

1. Pendahuluan & Konsep

2. Sumber Data (Validasi)

3. Algoritma Visualisasi

4. Legenda Visual